




**Supplementary information, Fig. S7. Robust and broad nAbs induced by CF501/RBD-Fc in rhesus macaques.**

**a** Dose-dependent curve of inhibitory activity against authentic SARS-CoV-2 by the plaque reduction assay in Vero-E6 cells. Data are shown as mean  $\pm$  sem.

**b** Correlation between PRNT<sub>50</sub> against authentic SARS-CoV-2 and ELISA binding IgG endpoint titers from day 0 to day 191.

**c, d** The number of IFN- $\gamma$ -secreting PBMCs was determined by ELISPOT after *ex vivo* stimulation with peptides from SARS-CoV-2 RBD at day 210. Representative images of ELISPOT wells are shown (c).

**e** Cross-nAb titers against SARS-CoV PsV, SARSr-CoV Rs3367 PsV and SARSr-CoV WIV1 PsV in macaques on day 28. Data are shown as mean  $\pm$  sem.

Statistical analyses were performed using one-way ANOVA for (d) \*  $P < 0.05$ , \*\*  $P < 0.001$ , \*\*\*  $P < 0.0001$ . Spearman rank test was used to perform correlation analysis.